Top Markets
Coin of the day
Daiichi Sankyo Company, Limited Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited

4568
주식 순위 #779
Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively... Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively involved in the research, development, manufacturing, importation, marketing, and distribution of a diverse array of medicinal products worldwide. Its extensive product lineup addresses numerous therapeutic areas. In oncology, key offerings include trastuzumab deruxtecan, an anti-HER2 antibody drug conjugate, alongside treatments like Gefitinib for malignant tumors, Bicalutamide for prostate cancer, and Tamoxifen, an anti-breast cancer agent. For pain management, the company provides mirogabalin and loxoprofen (an anti-inflammatory analgesic). Diabetes treatments feature teneligliptin/canagliflozin and teneligliptin, with colesevelam serving dual purposes for hypercholesterolemia and type 2 diabetes. Other notable prescription drugs include lacosamide (an anti-epileptic), prasugrel (an antiplatelet), denosumab (for osteoporosis and bone disorders), edoxaban (an anticoagulant), esomeprazole (for ulcer treatment), memantine (for Alzheimer's disease), and laninamivir (for influenza). The company also supplies olmesartan (an antihypertensive), levofloxacin (an antibacterial), pravastatin (for hypercholesterolemia), Silodosin (for dysuria), and ferric carboxymaltose/iron sucrose injections for anemia. Beyond prescription medications, Daiichi Sankyo markets popular consumer health brands such as Lulu (a combination cold remedy), Loxonin S (an antipyretic/anti-inflammatory painkiller), Transino (for melasma and skin improvement), Minon (skincare), and the oral care lines Breath Labo and Clean Dental. The company further contributes to public health with various vaccines, including adsorbed cell culture-derived influenza, influenza HA, measles-rubella combined, and mumps vaccines. Its operations also extend beyond human pharmaceuticals to include veterinary drugs, cosmetics, medical equipment, food products, drinking water, and the production of active pharmaceutical ingredients (APIs) and intermediates. Daiichi Sankyo is collaborating with Guardant Health on the development of Guardant360 CDx, a companion diagnostic for Enhertu, specifically for advanced metastatic non-small cell lung cancer. Founded in 1899, the company is headquartered in Tokyo, Japan.
주가
$17.82
마지막 동기화: 2026-09-11
시가총액
$32.43B
변동 (1일)
0.83%
변동 (1년)
-25.31%
국가
JP
거래 Daiichi Sankyo Company, Limited (4568)

카테고리

Daiichi Sankyo Company, Limited (4568)의 배당 이력
Daiichi Sankyo Company, Limited (주식 심볼: 4568)은 총 36회의 배당금을 지급했습니다.
모든 배당금의 합계 (주식 분할 반영): $7.57
배당 수익률 (TTM): 0.0272
Daiichi Sankyo Company, Limited (4568)의 2009부터 2026까지 배당 지급 내역
연간 배당 지급
연도 배당금 (주식 분할 조정됨) 변화
2026 (TTM) $0.2424 -46.06%
2025 $0.4494 16.09%
2024 $0.3871 58.39%
2023 $0.2444 16.66%
2022 $0.2095 -13.25%
2021 $0.2415 1.13%
2020 $0.2388 11.07%
2019 $0.215 2.87%
2018 $0.209 0.14%
2017 $0.2087 5.51%
2016 $0.1978 -43.47%
2015 $0.3499 -36.15%
2014 $0.548 -14.11%
2013 $0.638 -45.88%
2012 $1.18 52.19%
2011 $0.7746 7.33%
2010 $0.7217 -5.08%
2009 $0.7603 0.00%
모든 배당 지급 목록
연도 배당금 변화
2026 (TTM) $0.2424 -46.06%
2025 $0.4494 16.09%
2024 $0.3871 58.39%
2023 $0.2444 16.66%
2022 $0.2095 -13.25%
2021 $0.2415 -66.29%
2020 $0.7165 11.10%
2019 $0.6449 2.85%
2018 $0.627 0.14%
2017 $0.6261 5.51%
2016 $0.5934 4.77%
2015 $0.5664 3.34%
2014 $0.5481 -8.44%
2013 $0.5986 -83.08%
2012 $3.54 368.46%
2011 $0.755 9.23%
2010 $0.6912 -9.09%
2009 $0.7603 0.00%
유사 기업 또는 경쟁사의 배당 지급
회사 배당 지급 횟수 국가
215.00%
US
225.00%
US
53.00%
US
33.00%
CH
223.00%
US